Wockhardt · NSE: WOCKPHARMA · BSE: 532300
Q2 FY23 results · Jul–Sep 2022
Wockhardt reported revenue from operations of ₹679.00 crore (down 21.2% from Q2 FY22) and net loss of ₹207.00 crore for Q2 FY23 (Jul–Sep 2022), on a consolidated basis.
| Item | Q2 FY23 | Q2 FY22 | YoY | Q1 FY23 | QoQ |
|---|---|---|---|---|---|
| Revenue from operations | 679.00 | 862.00 | −21.2% | 595.00 | +14.1% |
| Other income | 57.00 | 5.20 | +996.2% | 57.00 | +0.0% |
| Total income | 736.00 | 867.20 | −15.1% | 652.00 | +12.9% |
| Profit before tax | (230.00) | (29.24) | Loss widened | (96.00) | Loss widened |
| Net profit for the period | (207.00) | 37.17 | Turned loss | (75.00) | Loss widened |
| Attributable to shareholders of the company | (189.00) | 33.53 | Turned loss | (67.00) | Loss widened |
| EPS, basic (₹) | (13.15) | 3.03 | not comparable | (4.64) | Loss widened |
| Net margin (%) | -30.5 | 4.3 | -12.6 |
| Item | Q2 FY23 | Q2 FY22 | YoY | Q1 FY23 | QoQ |
|---|---|---|---|---|---|
| Revenue from operations | 258.00 | 310.44 | −16.9% | 241.00 | +7.1% |
| Other income | 29.00 | 4.19 | +592.1% | 49.00 | −40.8% |
| Total income | 287.00 | 314.63 | −8.8% | 290.00 | −1.0% |
| Profit before tax | (115.00) | (89.49) | Loss widened | (54.00) | Loss widened |
| Net profit for the period | (75.00) | (63.70) | Loss widened | (37.00) | Loss widened |
| EPS, basic (₹) | (5.17) | (5.75) | not comparable | (2.62) | Loss widened |
| Net margin (%) | -29.1 | -20.5 | -15.4 |
Consolidated
- Filed with BSE
- 14 Nov 2022, 15:29 IST
- Board meeting
- 04 Nov 2022
- Period
- 01 Jul 2022 to 30 Sep 2022
- Review status
- Unaudited
- Source
- XBRL filing on BSE
Standalone
- Filed with BSE
- 14 Nov 2022, 15:29 IST
- Board meeting
- 04 Nov 2022
- Period
- 01 Jul 2022 to 30 Sep 2022
- Review status
- Unaudited
- Source
- XBRL filing on BSE